Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia

NAUnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2023

Conditions
Critical Limb Ischemia
Interventions
DEVICE

TGI SVF material via intramuscular injection

Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.

Trial Locations (1)

46202

Indiana University Hospital, Indianapolis

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

U.S. Army Medical Research and Development Command

FED

lead

Tissue Genesis

INDUSTRY

NCT02234778 - Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia | Biotech Hunter | Biotech Hunter